Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib versus imatinib in imatinib-resistant GIST after sunitinib failure/intolerance
2006-002267-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nilotinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Sep 2006; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2006-002267-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002267-11.